Clinuvel Pharmaceuticals Ltd represents values and a corporate philosophy focused on delivering innovative, science-driven therapeutic solutions. The company is committed to advancing knowledge and improving the lives of patients suffering from severe skin disorders. Clinuvel's passion for the scientific community and dedication to patient well-being is evident in their development of SCENESSE®, a groundbreaking drug for the treatment of rare genetic skin diseases. With a strong emphasis on research, development, and collaboration, Clinuvel Pharmaceuticals Ltd strives to provide innovative and effective treatments, revolutionizing the way severe skin disorders are managed.

Clinuvel Pharmaceuticals Ltd is primarily present in Australia, Europe, the United States, and other select regions globally. As a leading pharmaceutical company, Clinuvel focuses on developing and commercializing innovative therapies to treat various severe skin disorders. With a strong presence in these key markets, Clinuvel Pharmaceuticals Ltd strives to provide patients with effective and safe treatments to improve their quality of life.

Clinuvel Pharmaceuticals Ltd has achieved several significant milestones. Firstly, the company successfully obtained marketing approvals in the European Union for its product SCENESSE®, a first-line treatment for erythropoietic protoporphyria (EPP). This approval marked a major milestone for the company as it became the first-ever approved therapy for EPP patients. Additionally, Clinuvel Pharmaceuticals Ltd expanded its commercialization efforts by gaining market access in Switzerland, Australia, and the United States. Furthermore, the company demonstrated robust clinical trial data highlighting the safety and efficacy of SCENESSE®. Clinuvel's achievements in securing approvals, expanding market access and delivering substantial clinical evidence demonstrate its dedication towards improving the lives of patients with rare genetic disorders like EPP.

Clinuvel Pharmaceuticals Ltd is an Australian biopharmaceutical company specializing in the development and commercialization of therapies for genetic diseases. Founded in 1987, Clinuvel has dedicated years to research and development, focusing on photoprotection and pigmentation disorders. The company gained recognition for its flagship product, SCENESSE®, a treatment for the rare genetic disorder erythropoietic protoporphyria (EPP). Clinuvel Pharmaceuticals continues to explore potential applications of its innovative technology in various medical fields, aiming to improve the lives of patients worldwide. With a strong commitment to scientific excellence and continuous advancement, Clinuvel Pharmaceuticals Ltd remains a key player in the field of biopharmaceuticals.

The main competitors of Clinuvel Pharmaceuticals Ltd in the market are other pharmaceutical companies that specialize in developing and commercializing pharmaceutical products.

Clinuvel Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

The business model of Clinuvel Pharmaceuticals Ltd is focused on developing and commercializing pharmaceutical products for the treatment of severe genetic and skin disorders. The company specializes in innovative solutions for patients suffering from rare and ultra-rare diseases. With a strong emphasis on research and development, Clinuvel aims to improve the quality of life for individuals affected by these conditions. By leveraging its expertise in photoprotection and photorepair, Clinuvel seeks to address unmet medical needs, providing effective treatments that can significantly impact patients' lives. Clinuvel Pharmaceuticals Ltd is dedicated to advancing healthcare solutions and making a positive difference in the lives of those it serves.

Raportul Clinuvel Pharmaceuticals preț/beneficiu este 20,89.

Raportul Clinuvel Pharmaceuticals preț/vânzări este 7,80.

Scorul de calitate AlleAktien pentru Clinuvel Pharmaceuticals este 6/10.

Cifra de afaceri a Clinuvel Pharmaceuticals este de 95,50 milioane AUD.

Profitul Clinuvel Pharmaceuticals este 35,64 milioane AUD.

The Australian company Clinuvel Pharmaceuticals Ltd is a biotech company specializing in developing innovative therapeutics for various skin diseases. The company focuses on researching and developing products for the treatment of rare diseases and difficult-to-treat skin conditions. Clinuvel operates three main business lines: Pharma, Cosmeceutical, and Heritage. The Pharma division of Clinuvel is the flagship of the company and includes a wide range of medical products for the treatment of various skin diseases. Clinuvel has developed an innovative drug called SCENESSE, which is approved for the treatment of patients with Erythropoietic Protoporphyria (EPP). EPP is a rare genetic disorder that causes patients to have an extremely painful sensitivity to visible light. The Cosmeceutical division of Clinuvel focuses on the development of cosmetic products that combat skin aging and keep the skin healthy and youthful. The products are typically enriched with powerful antioxidants and moisturizing agents to protect the skin and reduce the appearance of aging signs. The Heritage division of Clinuvel specializes in developing products for maintaining cultural identity and heritage preservation. These products relate to the traditions and customs of specific cultures and communities, thereby supporting the preservation of these important cultural features. Clinuvel's business model is based on a strong research and development strategy to create innovative products that provide clinical benefits and improve patients' lives. The company also has a strong focus on compliance regulations and the safety of its products. To achieve its goals, Clinuvel has established a global presence and works closely with leading experts in the pharmaceutical and biotechnology industry. The company also has strategic partnerships with non-profit organizations and other companies to expand its range of products and services. Clinuvel's goal is to provide groundbreaking solutions for the treatment of skin diseases while improving the quality of life for patients. The company aims to expand its global presence by remaining innovative and actively seeking new partnerships.

Clinuvel Pharmaceuticals distribuie un dividend de 0,06 AUD în 1 plăți anuale.

Clinuvel Pharmaceuticals distribuie un dividend de 1 ori pe an.

Codul ISIN pentru Clinuvel Pharmaceuticals este AU000000CUV3.

Codul WKN al Clinuvel Pharmaceuticals este A0JEGY.

Ticker-ul pentru Clinuvel Pharmaceuticals este CUV.AX.

În ultimele 12 luni, Clinuvel Pharmaceuticals a plătit un dividend în valoare de 0,07 AUD . Aceasta corespunde unei randamente a dividendului de aproximativ 0,49 %. Pentru următoarele 12 luni, Clinuvel Pharmaceuticals va plăti probabil un dividend de 0,08 AUD.

Randamentul dividendelor pentru Clinuvel Pharmaceuticals este în prezent de 0,49 %.

Clinuvel Pharmaceuticals plătește un dividend trimestrial. Acesta este distribuit în lunile octombrie, octombrie, octombrie, octombrie.

Clinuvel Pharmaceuticals a plătit dividende în fiecare an, în ultimii 13 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0,08 AUD. Acest lucru corespunde unei randamente a dividendelor de 0,56 %.

Clinuvel Pharmaceuticals este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Clinuvel Pharmaceuticals de la 20.09.2024 în valoare de 0,071 AUD, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 05.09.2024.

Ultima plată a dividendului a fost efectuată la 20.09.2024.

În anul 2023, Clinuvel Pharmaceuticals a distribuit 0,071 AUD sub formă de dividende.

Dividendele de la Clinuvel Pharmaceuticals sunt distribuite în AUD.